Re: TDM-1 side effects
One interesting drug to watch for will be everolimus (Affinitor). There is currently a Phase III clinical trial for MBC, but I believe this is a trial primarily as a first line of treatment.
In any case, the mTOR inhibitor everolimus is thought to cross the BBB. Everolimus has FDA approval for renal cancer, but not yet for breast cancer. Phase I and Phase II trials for MBC have been quite promising.
|